Point72 Asset Management
YMAB

Point72 Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Point72 Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-550
Closed -$4.31K – 2624
2024
Q4 		$4.31K Sell
550
-94,833
-99% -$1.15M ﹤0.01% 2035
2024
Q3 		$1.25M Sell
95,383
-263,562
-73% -$3.34M ﹤0.01% 1342
2024
Q2 		$4.34M Sell
358,945
-1,168,155
-76% -$15.8M 0.01% 876
2024
Q1 		$24.8M Buy
+1,527,100
New +$20.6M 0.06% 385
2023
Q4 		– Sell
-79,600
Closed -$434K – 2933
2023
Q3 		$434K Sell
79,600
-303,987
-79% -$1.77M ﹤0.01% 1558
2023
Q2 		$2.6M Buy
383,587
+26,369
+7% +$198K 0.01% 986
2023
Q1 		$1.79M Sell
357,218
-92,212
-21% -$377K 0.01% 999
2022
Q4 		$2.19M Buy
+449,430
New +$3.27M 0.01% 922
2019
Q3 		– Sell
-30,000
Closed -$686K – 1513
2019
Q2 		$686K Buy
+30,000
New +$689K ﹤0.01% 806
2018
Q4 		– Sell
-5,000
Closed -$133K – 1251
2018
Q3 		$133K Buy
+5,000
New +$127K ﹤0.01% 967

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Point72 Asset Management's YMAB Position: Q1 2025 in Review

Point72 Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 550 shares — an estimated $4.31K sold.

Point72 Asset Management first reported a position in YMAB in Q3 2018 and held it in 10 quarters. The position peaked at $24.8M in Q1 2024. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Point72 Asset Management reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 550 Y-mAbs Therapeutics shares in Q1 2025, an estimated $4.31K.
  • Point72 Asset Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 10 quarters.
  • Point72 Asset Management's Y-mAbs Therapeutics position peaked at $24.8M in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.